News | August 31, 2025
Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Replicate will receive research funding and could potentially receive up to approximately US$550 million
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Subscribe To Our Newsletter & Stay Updated
